Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights From Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases.

anca-related vasculitis central hypothyroidism hif-ph inhibitors renal anemia roxadustat

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2024
Historique:
accepted: 06 06 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: epublish

Résumé

The introduction of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors in Japan in 2019 for treating renal anemia in hemodialysis patients has resulted in an adverse event: central hypothyroidism. Although this adverse event was not widely recognized by the public, it was first documented in Japan in 2021. Despite limited case reports on roxadustat, an oral HIF-PH inhibitor that induces central hypothyroidism, this condition typically improves rapidly upon discontinuation of the drug. In this report, we present rare cases of roxadustat-induced central hypothyroidism in two patients: a woman in her 80s and a man in his 60s, neither of whom had prior thyroid disease. Both patients developed central hypothyroidism shortly after starting roxadustat treatment for renal anemia associated with antineutrophil cytoplasmic antibody-related vasculitis. Notably, neither patient had pituitary tumors or other pituitary hormone disorders. Thyroid function improved with levothyroxine treatment, even when oral roxadustat was continued. Roxadustat may induce central hypothyroidism, highlighting the importance of regularly measuring and evaluating thyroid function when administering this drug to monitor possible changes in thyroid hormone levels.

Identifiants

pubmed: 38975517
doi: 10.7759/cureus.61843
pmc: PMC11227460
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

e61843

Informations de copyright

Copyright © 2024, Omote et al.

Déclaration de conflit d'intérêts

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Daichi Omote (D)

Nephrology, Narita Red Cross Hospital, Narita-shi, JPN.

Nobuhiko Kuramoto (N)

Nephrology, Narita Red Cross Hospital, Narita-shi, JPN.

Atsuko Tomikawa (A)

Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN.

Masahiro Yasui (M)

Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN.

Masashi Fukuta (M)

Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN.

Masaki Hiraguri (M)

Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN.

Classifications MeSH